SARS-CoV-2 Clinical Trial
Official title:
CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid.
This is a Phase 1, open-label study to evaluate the safety profile of CORVax +/- pIL-12, (electroporated SARS-CoV-2 spike (S) protein plasmid DNA vaccine with or without the combination of electroporated IL-12p70 plasmid), given as prime & boost doses, four weeks apart, in healthy volunteers, divided into age groups of 18-50 versus > 50 years old. IL-12p70 plasmid DNA electroporation (tavokinogene telseplasmid) has been extensively studied in over 209 subjects across 11 trials including later stage human cancer trials with more than 1000 administrations. The IGEA CLINIPORATOR® system is approved for clinical use in Europe, but remains investigational in this study. One participant will initially be enrolled to each of four cohorts and monitored over a 7-day DLT window: 1A. Age 18-50; CORVax. 1. B. Age 18-50; CORVax + pIL-12. 2. A. Age > 50; CORVax. 2B. Age > 50; CORVax + pIL-12. If after 7 days, no DLT are observed, the cohort may proceed to enroll a second participant. If after monitoring the second participant for 7 days, no DLT are observed, the cohort may proceed to enroll a third participant. If after monitoring the third participant for 7 days, no DLT are observed, the cohort may proceed to enroll six additional participants, for a total of nine participants per cohort using a (1+1+1, +6) design. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT05584202 -
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
|
Phase 2 | |
| Completed |
NCT04579549 -
Repeat Testing for SARS-CoV-2
|
N/A | |
| Active, not recruiting |
NCT05547243 -
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China
|
N/A | |
| Recruiting |
NCT04613310 -
PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19)
|
N/A | |
| Recruiting |
NCT04747574 -
Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection
|
Phase 1 | |
| Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
| Terminated |
NCT04447404 -
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
|
Phase 2 | |
| Withdrawn |
NCT04388709 -
Interferon Lambda Therapy for COVID-19
|
Phase 2 | |
| Active, not recruiting |
NCT05550142 -
A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China
|
N/A | |
| Completed |
NCT04620798 -
Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
|
N/A | |
| Active, not recruiting |
NCT05547256 -
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China
|
N/A | |
| Completed |
NCT04561102 -
Evaluation of the COVIDSeq Test in Nasal Swab and Saliva From a COVID-19 Asymptomatic Population
|
||
| Completed |
NCT04452604 -
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
|
||
| Completed |
NCT05366322 -
A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults
|
||
| Terminated |
NCT04958304 -
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
|
||
| Completed |
NCT04526769 -
Detecting SARS-CoV-2 in Tears
|
||
| Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A |